d-OSAB™ technology targets diseases or conditions that exhibit underlying inflammation or have an inflammatory component. Clinical targets include:

Cardiovascular: atherosclerosis, peripheral arterial occlusive disease, congestive heart failure, hypertension, cerebrovascular disease (stroke), dyslipidemia, and vasospastic disorders including Raynaud’s disease.

Inflammatory diseases and conditions include: rheumatoid arthritis, multiple sclerosis, systemic lupus erythromatosis (SLE), scleroderma, diabetes, inflammatory bowel disease, psoriasis, pemphigus, atherosclerosis, chronic heart failure, graft versus host reaction and tissue transplant rejection.

Neuro-degenerative disorders include: Alzheimer's disease, Parkinson's Disease and senile dementia.

In addition, AcquiSci’s platform technology embodying precise, measured delivery of an absorbed dose of oxidative stress has application to inactivation of infectious prion proteins, the causative agent underlying Mad Cow and Creutzfeldt-Jakob Diseases.